KOL Views Preview: Is Enhertu’s DESTINY to displace Kadcyla in 2L HER2+ breast cancer – and beyond?

Enhertu (trastuzumab deruxtecan) bested fellow antibody-drug conjugate Kadcyla (trastuzumab emtansine) this week in the Phase III DESTINY-Breast03 trial as second-line therapy for HER2-positive breast cancer. The head-to-head success validates Daiichi Sankyo’s development strategy as well as AstraZeneca’s faith, and sets the stage for possible further expansion into the upfront and even HER2-low settings.

To provide FirstWord readers with rapid feedback on how and how quickly Enhertu is likely to impact prescribing decisions in HER2-positive breast cancer, we are hosting an expert call with a key opinion leader (KOL) next week.

Key topics that will be discussed during the call include, among other things… what has your experience been like so far using Enhertu in third-line and later patients; how has the drug’s safety profile stacked up relative to your expectations; how impressed are you by the top-line announcement that Enhertu significantly prolonged progression-free survival (PFS) versus Kadcyla as second-line therapy; how much of a PFS benefit relative to Kadcyla would Enhertu need to achieve in order to drive uptake and do you feel this is likely; what is your level of confidence that Enhertu will eventually achieve significance on the secondary endpoint of overall survival (OS); how important is demonstrating an OS advantage to adoption; what will you be most interested in seeing when detailed DESTINY-Breast03 data are presented; is there anything on the safety side that you will be one the eye out for; are encouraged you by the lack of grade 4/5 cases of interstitial lung disease (ILD); and what is your confidence level that Enhertu will succeed in the front-line metastatic, adjuvant and HER2-low settings, and has it changed due to its success in DESTINY-Breast03?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the competition among HER2-targeting breast cancer drugs.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord Pharma would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.